Jennifer

– Industry veteran strengthens Pyxis team with expertise in clinical development, medical affairs and antibody-drug conjugates (ADCs) – CAMBRIDGE, Mass., Sept. 14, 2021 – Pyxis Oncology (“Pyxis” or the “Company”) today announced the appointment of Jay M. Feingold, M.D., Ph.D., as Chief Medical Officer. “Jay’s track record of success taking oncology ADC programs from discovery […]

– Veteran biotech executive adds financial and operational expertise to growing Pyxis team – CAMBRIDGE, Mass., August 31, 2021 – Pyxis Oncology (“Pyxis” or the “Company”) today announced the recent appointment of Pamela Yanchik Connealy, M.B.A., as its Chief Financial Officer.  Ms. Connealy will be leading the Finance, Investor Relations and Human Resources functions at

– Steve Monks, Ph.D., appointed as Chief Technical Officer, brings 20+ years in drug development and CMC, Quality, and Regulatory operations –– Ritu Shah, PMP, appointed as Chief Operating Officer, brings 20+ years of industry experience specializing in portfolio management and strategic planning –– Christoph Rader, Ph.D., and Anthony W. Tolcher, M.D., join Scientific Advisory

LEXINGTON & CAMBRIDGE, Mass., May 25, 2021 – Alloy Therapeutics (“Alloy”) and Pyxis Oncology (“Pyxis”) today announced the formation of a joint venture named Kyma Therapeutics to develop immune-modulating antibodies for novel targets in cancer and autoimmune diseases. Kyma Therapeutics will advance programs directed to immune-modulating targets identified by Pyxis. Alloy Discovery Services will generate

— Pyxis Oncology to host webcast with Key Opinion Leaders (KOLs) on April 27, 2021 at 1:00pm ET — CAMBRIDGE, Mass., April 27, 2021 – Pyxis Oncology (“Pyxis” or the “Company”) today announced the targets of its three antibody-drug conjugate (ADC) candidates along with additional details and preclinical data supporting the potential of its ADC